The use of mono- and combination drug therapy in men and women with lower urinary tract symptoms (LUTS) in the UK: a retrospective observational study

Ali, Mahmood; Landeira, Margarita; Covernton, Patrick J. O.; Choudhury, Nurul; Jaggi, Ashley; Fatoye, Francis; van Maanen, Rob

doi:10.1186/s12894-021-00881-w

Table 7 Persistence at 1 month, 6 months and 1 year in male LUTS (including OAB) sub-cohort

From: The use of mono- and combination drug therapy in men and women with lower urinary tract symptoms (LUTS) in the UK: a retrospective observational study

	N	1 month % [95% CI]	6 months % [95% CI]	1 year % [95% CI]	Median (months) [95% CI]
All	12,383	72.9	34.8	25.2	2.5
		[72.1, 73.6]	[33.9, 35.6]	[24.4, 26.0]	[2.4, 2.7]
Number of patients still at risk^a		9024	4304	3105
Monotherapy	7946	65.6	37.6	27.7	2.5
		[64.5, 66.6]	[36.5, 38.6]	[26.8, 28.7]	[2.3, 2.7]
Number of patients still at risk^a		5211	2986	2193
Combination drug therapy	4437	85.9	29.7	20.6	2.5
		[84.9, 86.9]	[28.4, 31.1]	[19.4, 21.8]	[2.4, 2.7]
Number of patients still at risk^a		3813	1318	912
Monotherapy
Darifenacin	47	74.5	34.0	27.7	2.3
		[59.4, 84.6]	[21.0, 47.5]	[15.9, 40.8]	[1.7, 5.4]
Number of patients still at risk^a		35	16	13
Fesoterodine	285	67.4	41.8	28.1	3.8
		[61.6, 72.5]	[36.0, 47.4]	[23.0, 33.4]	[2.7, 5.2]
Number of patients still at risk^a		192	119	80
Flavoxate	49	59.2	26.5	20.4	1.8
		[44.2, 71.4]	[15.2, 39.3]	[10.5, 32.6]	[1.0, 3.1]
Number of patients still at risk^a		29	13	9
Mirabegron	503	79.5	53.1	40.9	6.7
		[75.7, 82.8]	[48.6, 57.3]	[36.6, 45.2]	[5.2, 9.5]
Number of patients still at risk^a		400	267	204
Oxybutynin	2613	59.6	33.5	25.1	1.8
		[57.7, 61.4]	[31.7, 35.3]	[23.5, 26.8]	[1.7, 1.9]
Number of patients still at risk^a		1557	875	653
Propiverine	18	55.6	27.8	22.2	1.4
		[30.5, 74.8]	[10.1, 48.9]	[6.9, 42.9]	[0.9, 4.9]
Number of patients still at risk^a		10	5	4
Solifenacin	2759	70.2	40.2	29.5	3.2
		[68.5, 71.9]	[38.4, 42.1]	[27.8, 31.2]	[2.9, 3.6]
Number of patients still at risk^a		1938	1110	812
Tolterodine	1445	61.2	33.7	24.8	1.8
		[58.6, 63.6]	[31.3, 36.1]	[22.6, 27.1]	[1.8, 2.2]
Number of patients still at risk^a		884	487	355
Trospium	227	73.1	41.4	27.8	3.4
		[66.9, 78.4]	[35.0, 47.7]	[22.1, 33.7]	[2.2, 4.9]
Number of patients still at risk^a		166	94	63
Combination drug therapy
Alfuzosin + solifenacin	47	87.2	40.4	29.8	4.1
		[73.8, 94.1]	[26.5, 53.9]	[17.6, 43.0]	[2.1, 6.9]
Number of patients still at risk^a		41	19	14
Doxazosin + oxybutynin	95	87.4	18.9	NO	2
		[78.8, 92.6]	[11.8, 27.4]	–	[1.8, 2.3]
Number of patients still at risk^a		83	18	13
Doxazosin + solifenacin	114	89.5	36.0	20.2	3.8
		[82.2, 93.9]	[27.3, 44.7]	[13.4, 28.0]	[2.8, 4.7]
Number of patients still at risk^a		102	41	23
Doxazosin + tolterodine	69	87.0	39.1	29.0	3.1
		[76.4, 93.0]	[27.7, 50.4]	[18.8, 39.9]	[2.1, 6.4]
Number of patients still at risk^a		60	27	20
Dutasteride + solifenacin + tamsulosin	79	89.9	27.8	21.5	2.4
		[80.8, 94.8]	[18.5, 38.0]	[13.3, 31.1]	[2.1, 3.6]
Number of patients still at risk^a		71	22	17
Fesoterodine + tamsulosin	83	85.5	28.9	NO	2.6
		[75.9, 91.5]	[19.6, 38.9]	–	[2.1, 3.3]
Number of patients still at risk^a		71	24	12
Finasteride + oxybutynin	62	88.7	32.3	17.7	2.5
		[77.8, 94.5]	[21.1, 43.9]	[9.5, 28.1]	[1.8, 3.6]
Number of patients still at risk^a		55	20	11
Finasteride + oxybutynin + tamsulosin	111	91.0	30.6	19.8	2.3
		[83.9, 95.0]	[22.3, 39.3]	[13.0, 27.7]	[2.0, 3.6]
Number of patients still at risk^a		101	34	22
Finasteride + solifenacin	96	90.6	44.8	32.3	3.9
		[82.8, 95.0]	[34.7, 54.4]	[23.2, 41.7]	[2.1, 6.9]
Number of patients still at risk^a		87	43	31
Finasteride + solifenacin + tamsulosin	233	91.0	45.1	28.8	4
		[86.5, 94.0]	[38.6, 51.3]	[23.1, 34.7]	[3.4, 6.2]
Number of patients still at risk^a		212	105	67
Finasteride + tamsulosin + tolterodine	57	96.5	40.4	28.1	3.9
		[86.7, 99.1]	[27.7, 52.7]	[17.2, 40.0]	[2.8, 6.7]
Number of patients still at risk^a		55	23	15
Finasteride + tolterodine	41	85.4	29.3	22.0	1.7
		[70.3, 93.1]	[16.4, 43.4]	[10.9, 35.5]	[1.5, 3.9]
Number of patients still at risk^a		35	12	9
Mirabegron + solifenacin	95	85.3	NO	NO	2
		[76.4, 91.0]	–	–	[1.7, 2.5]
Number of patients still at risk^a		81	11	6
Mirabegron + tamsulosin	96	82.3	37.5	29.2	3.2
		[73.1, 88.6]	[27.9, 47.1]	[20.5, 38.4]	[2.2, 4.7]
Number of patients still at risk^a		79	36	28
Oxybutynin + solifenacin	102	84.3	NO	NO	1.8
		[75.7, 90.1]	–	–	[1.6, 1.9]
Number of patients still at risk^a		86	4	2
Oxybutynin + tamsulosin	364	82.4	26.9	16.5	2.1
		[78.1, 86.0]	[22.5, 31.6]	[12.9, 20.5]	[2.0, 2.3]
Number of patients still at risk^a		300	98	60
Solifenacin + tamsulosin	902	86.7	39.9	29.4	3.6
		[84.3, 88.7]	[36.7, 43.1]	[26.4, 32.4]	[3.2, 4.1]
Number of patients still at risk^a		782	360	264
Solifenacin + tolterodine	114	77.2	NO	NO	1.6
		[68.3, 83.9]	–	–	[1.5, 1.8]
Number of patients still at risk^a		88	6	2
Tamsulosin + tolterodine	248	82.3	33.5	24.2	3.3
		[76.9, 86.5]	[27.7, 39.4]	[19.1, 29.7]	[2.6, 4.0]
Number of patients still at risk^a		204	83	60
Tamsulosin + trospium	65	90.8	41.5	29.2	4.7
		[80.6, 95.7]	[29.5, 53.1]	[18.8, 40.5]	[2.9, 7.1]
Number of patients still at risk^a		59	27	19
Other combinations	1364	85.1	22.4	15.9	2.1
		[83.1, 86.9]	[20.2, 24.6]	[14.0, 17.9]	[2.0, 2.2]
Number of patients still at risk^a		1161	305	217

Not Observable indicates that the number of patients still at risk was below the 20% of the initial sample threshold required to calculate persistence, or the median was not reached
CI: confidence interval; LUTS: lower urinary tract symptoms; NO: not observable; OAB: overactive bladder ^aNumber of patients still observable at a given time and for whom no events occurred

Back to article page

ISSN: 1471-2490

Contact us

General enquiries: journalsubmissions@springernature.com

BMC Urology

Contact us